ing that these cells represented monocyte precursors. A distinct subset of CD34+ cells expressed GM-CSF receptors at low-to-intermediate levels and proliferated strongly in the presence of GM-CSF during short-term culture, but produced very few erythroid or monomyeloid colonies after longer culture periods. Most colony-forming cells, also those responsive t o GM-CSF alone, were recovered in the subset of CD34+ cells on which GM-CSF receptors were virtually undetectable. These cells showed weaker proliferation in short-term proliferation assays than the CD34'1GM-CSF-receptor-intermediate cells, consistent with an immature phenotype. The results show that GM-CSF-receptor expression is initiated in a subset of immature, CD34b'0M/RhLA-DRd"'' cells and is progressively increased during differentiation into mature granulocytes and monocytes. The method used provides a new way t o deplete developmentally early CD34' cell of differentiating granulocyte and monocyte precursor cells. 0 1994 by The American Society of Hematology.
leukemic cell lines, such as MO'~%,~'-*" HL60,*'.*' and KGla.'' High-affinity GM-CSF receptors have been found on purified human monocytes, which display low-affinity sites as well, whereas neutrophils bind GM-CSF with intertion of one a-subunit with two or more P-subunits.I6 Highaffinity binding sites have been detected on morphologically recognizable granulocyte precursors from human bone marrow (BM)." In addition, by using specific monoclonal antibodies (MoAbs), the common P-subunit of the GM-CSF receptor, IL-3 receptor and IL-5 receptor has been identified on the small subset of BM cells that express the CD34 antigen, which indicates that functional GM-CSF receptors may also be present on immature hematopoietic cells." Analysis of the GM-CSF receptor distribution on hematopoietic cells to define the functions of GM-CSF in hemopoiesis is difficult to achieve with conventional techniques using the radiolabeled ligand because of the low frequencies of the cells involved. In addition, analysis of the expression of individual subunits of the GM-CSF receptors, using antibodies or cDNA probes, may not be indicative of the presence of functional, high-affinity receptors on these cells. In previous studies, flow-cytometric detection methods using biotin-labeled hematopoietic growth factor (HGF) molecules have been used in conjunction with phycoerythrin-conjugated streptavidin to detect cells capable of binding biologically active ligands by multiparameter flow cyt~metry.~~-'" This approach, which allows for identification of receptor-expressing subsets in heterogeneous cell populations as well as characterization of receptor-expressing cells by parameters such as light scatter and specific cell surface markers, has been applied to examine the cellular distribution of the receptors for erythropoietin (Epo), IL-6 and G-CSF on BM s~b s e t s .~~~' "
In the present study we have used biologically active biotin-labeled GM-CSF to examine the distribution 
MATERIALS AND METHODS

Growth factors.
Recombinant human GM-CSF free of carrier proteins was a gift from Genetics Institute (Cambridge, MA). GM-CSF was biotin-labeled, essentially as described for IL-6?9 Briefly, 5 pg of GM-CSF in 0.1 m o m sodium bicarbonate buffer pH 8.4, containing 0.02% (wt/vol) Tween-20, was incubated with a 1000-fold molar excess of N-hydroxy-succinymidyl-biotin (Pierce, Rockford, IL) for 2 hours at 2OT, after which biotin-labeled GM-CSF molecules were separated from free reagent by size exclusion chromatography on a l-mL Sephadex G-25 column (Pharmacia, Uppsala, Sweden), equilibrated in phosphate-buffered saline, containing 0.02% (wt/vol) Tween-20. Recovery of biotin-labeled GM-CSF ranged between 10% and 50% for individual preparations, as tested in a 'H-thymidine uptake assay using M07E cells." Only batches of which greater than 99% of biologically active GM-CSF was biotinlabeled, as tested by absorption to streptavidin-agarose beads (Sigma Chemical CO, St Louis, MO), were used.
Procurement of BM and PB cells. PB was obtained by vena puncture. BM was collected from young-adult rhesus monkeys (Mucucu muluttu), bred at the TNO Primate Center, Rijswijk, The Netherlands, by piercing the head of the humeral shaft to obtain small samples or by piercing the knee joint into the femoral shaft in case larger amounts of BM were needed." To enrich for progenitor cells, buffy-coat cells were subjected to a discontinuous bovine serum albumin (BSA)-density gradient and low-density cells were colle~ted.'~~'' Residual red blood cells were removed by osmotic lysis using 10 mmoVL potassium bicarbonate, 155 mmom ammonium chloride, pH 7.4, containing 0.1 mmolR. EDTA. CD34' cells were isolated by immunomagnetic separation, using an IgG2A antibody against CD34 (MoAb 561, kindly provided by T. Egeland, University of Oslo, Norway) that was noncovalently linked to rat-antimouse IgG2A beads (Dynal, Oslo, Norway). CD34+ cells devoid of the anti-CD34 antibody were recovered by competitive elution using a polyclonal antibody against the Fab part of the anti-CD34 antibody (Detachabead, D~nal).'~ Before staining, cells were incubated for 30 to 45 minutes at 37°C in a large volume of HEPES-buffered Hanks' balanced salt solution (HBSS), containing 2% (vol/vol) fetal calf serum (FCS)(HF buffer), followed by washing with ice-cold HF buffer, containing 0.05% (wt/vol) sodium azide (HFN) to remove possible receptor-bound natural GM-CSF and allow reexpression of unoccupied receptors.
Binding of biotin-labeled GM-CSF to cells. One million cells were incubated with biotin-labeled GM-CSF (at a concentration of 1 nmol/L, unless indicated otherwise) in 100 pL HFN for 15 hours on ice. Nonspecific binding of biotin-GM-CSF was evaluated in the presence of a 100-200-fold molar excess of nonlabeled GM-CSF. After incubation, cells were washed twice and incubated with streptavidin-phycoerythrin (SA-WE; Molecular Probes, Eugene, OR) at a concentration of 7 pglmL for 1 hour on ice. In most experiments, the fluorescence intensity was amplified by sequential incubation with a biotin-labeled anti-RPE MoAb and a second incubation with SA-RPE, as described.28 For two-color analysis, cells were stained during the last SA-WE incubation step with a MoAb against human CD34 that reacts with rhesus monkey CD34 (MoAb 566) and had been fluoresceinated by conjugation with fluorescein isothiocyanate (FITC; Sigma) according to standard procedures. For three-color analysis, cells were simultaneously incubated with SA-W E , FITC-labeled anti-CD34 and a peridinin chlorophyll (PerCP) conjugated MoAb against human HLA-DR that reacts with rhesus Clonogenic assay of sorted cells. Cells were plated in 35-mm dishes (Becton Dickinson) in 1 mL a " E M (GIBCO, Gaithersburg, MD), containing 0.8% methylcellulose, 5% FCS, 1% BSA, glutamine (2 mmoVL), insulin (10 pg/mL), linoleic acid, and cholesterol (1.5 X lo-' morn), sodium selenite (1 X 10" mom), nucleosides (each at 1 mg/mL), 2-mercaptoethanol (1 X mom), iron-saturated human transferrin (0.6 mg/mL), penicillin (100 U/mL) and streptomycin (50 pg/mL). For erythroid burst-forming units (BFUEs), cultures were supplemented with hemin (2 X mom), human recombinant Epo (4 U/mL; Behringwerke AG, Marburg, Germany) and Kit-ligand (stem-cell factor, S C F 200 ng/mL; provided by Dr S . Gillis, Immunex, Seattle, WA). For granulocytemacrophage colony-forming units (CFU-GMs), cultures were supplemented with human recombinant GM-CSF (5 ng/mL; Behringwerke AG) alone or with recombinant rhesus monkey IL-3 (30 ng/mL) or with L -3 plus Kit ligand. Unsorted cells were plated at 5 X lo4 cells per dish and sorted cells were plated at concentrations ranging between 1,000 and 5,000 per dish. Colonies were counted at day 12. CFU-GM included CFU-GM, CFU-G, and CFU-M. The recovery of progenitors in sorted fractions was calculated relative to the sort control, which was set at 100%. Colony numbers and recovery represent the mean 2 SE of duplicate dishes. SE was calculated on the assumption that crude colony counts are Poisson distributed.
Short-term proliferation assays. To measure GM-CSF responsiveness, 5,000 to 7,500 sorted BM cells were cultured in the presence or absence of GM-CSF (5 ng/mL) in triplicate in wells of 96-well tissue culture plates. After 48 hours, 'H-thymidine (0.25 mCi/ well) was added to each well and the cultures were continued for another 15 to 20 hours. Cells were then collected using an automatic cell harvester (Skatron, Norway) and 'H-thymidine incorporation was measured in a liquid scintillation counter (Pharmacia-LKB, Bromma, Sweden). Cells in parallel cultures were used for analysis of morphology after centrifugation onto microscope slides and MayGrilnwald-Giemsa staining. Adherent cells were cultured directly in 100 pL droplets of culture medium on sterile microscope slides.
RESULTS
Detection of GM-CSF receptors on cell lines and PB cells.
The specificity and sensitivity of biotin-labeled GM-CSF for detecting GM-CSF-receptor expressing cells was assessed by flow cytometric analysis of two cell lines known to express GM-CSF receptors, M07E and HL60, and one recep- tor-negative cell line, KGla. M07E cells, which express 300 to 400 high-affinity were stained specifically by biotin-labeled GM-CSF (Fig 1A) . GM-CSF receptors could also be detected on HL60 cells, but at lower intensity than on M07E cells, which was consistent with the lower GM-CSF-receptor expression reported for HL60 cells, ie, 50 to 150 sites per cell (Fig 1B) .2',22 KGla cells displayed only background fluorescence (Fig LC) , in concordance with the absence of detectable receptor expression as determined with radiolabeled GM-CSF."
Fluorescence intensity
GM-CSF-receptor expression was examined on PB lymphocytes, monocytes and granulocytes, identified by characteristic forward-angle and right-angle light-scatter properties (Fig 2A) . GM-CSF-receptor expression could be readily detected on monocytes (Fig 2C) and granulocytes (Fig 2D) , WOGNUM ET AL whereas lymphocytes did not express detectable levels. (Fig  2B) . The fluorescence intensity was twofold to threefold higher on monocytes than on granulocytes, suggesting either more receptors or a greater binding affinity (Fig 2) . These experiments were performed using biotin-GM-CSF at concentrations of 1 nmoVL, which is saturating for high-affinity receptors and close to the dissociation constant of low-aftinity sites. In titration experiments, GM-CSF-receptor expression on monocytes and Mo7E cells was still detectable using biotin-GM-CSF concentrations as low as 30 pmol/L, which may indicate that detectable binding to these cells was mainly attributable to high-affinity sites. Specific binding to granulocytes required higher concentrations, ie. 60 to 120 pmoVL, which is consistent with the presence of receptors that bind GM-CSF with intermediate affinity on these GM-CSF receptors on CD34-BM cells. The GM-CSFreceptor distribution of unfractionated BM was grossly similar to that of PB cells (not shown). To examine GM-CSFreceptor expression on immature hematopoietic cells, GM-CSF-receptor expression was compared with expression of the CD34 antigen. These experiments were performed using the low-density fraction of BM cells, which generally contains 5% to 15% of nucleated cells and 50% to 95% of the clonogenic progenitor cell^.'^ As shown in Fig 3A, GM-CSF receptors were detected on at least two subsets of CD34-cells and also on subsets of the =lo% of low-density BM cells that expressed the CD34 antigen. The light-scatter properties of the CD34-cells that expressed high GM-CSFreceptor levels were similar to those observed for mature monocytes in unfractionated BM and in PB (Fig 3C) . Purified CD34-/GM-CSF-re~eptor~"~~' cells obtained by cell sorting consisted of large cells that morphologically resembled monocytes (not shown). Upon restaining and FACScan analysis, the sorted cells were found to express high levels of the CD1 l b and RhLA-DR antigens, which confirmed that these cells were relatively mature cells of the monocyte lineage (Fig 4, A and B) . The fluorescence intensity of the CD34-/GM-CSF-receptor intermediate cells was similar to that obtained for mature granulocytes and granulocyte precursors in PB and unfractionated BM (Fig 3A) . Sorted CD34-/GM-CSF-receptor intermediate cells were more heterogeneous with respect to morphology, light-scatter properties (Fig 3D) , CD1 lb expression ( Fig 4C) and RhLA-DR expression (Fig 4D) than the CD34-/GM-CSF-receptorhrLght cells. Morphologically, most cells resembled differentiated neutrophils with bandshaped and segmented nuclei, whereas a smaller proportion of cells had less-differentiated blast cell morphology (not shown). Approximately 70% to 75% of sorted CD34-/GM-CSF-receptor intermediate cells expressed high CD1 Ib levels but were almost negative for RhLA-DR (Fig 4, C . .. (Fig 3D) . The 25% to 30% of CD34-/GM-CSFreceptor intermediate cells that were RhLA-DRh"ght and CD1 lb-intermediate had lower right-angle light scatter ( Fig  3D) , which is characteristic for less-differentiated myeloblasts (Fig 4, C and D) . As was expected from their relatively mature stage of differentiation, CD34-/GM-CSF-recepand CD34-/GM-CSF-receptor intermediate cells did not proliferate in cultures stimulated with GM-CSF (Fig 5) .
Fig 6. Morphology of rhesus monkey BM cells sorted on the basis of CD34 and GMGSF-receptor levels. CD34' cells with high (A,BI. intermediate (CD) and undetectable (E,F) GM-CSF-receptor expression, immediately after sorting (A,C,E) and after 3 days culture with GM-CSF (B,D,F). A and C to F represent photomicrographs of May-GrOnwaldlGiemsa
GM-CSF receptors on CD34+ cells. Staining with biotin-GM-CSF distinguished three subsets of CD34+ cells (Fig 3A) . One subset expressed GM-CSF receptors at relatively high levels, similar to those observed on the CD34-/ GM-CSF-receptorh"gh' monocyte precursors and had lightscatter properties that were similar to those of monocytes (Fig 3F) . GM-CSF-receptor expression appeared to increase with decreasing CD34 expression, which may be taken as evidence that this subset represents differentiating cells ( Fig  3A) . Sorted CD34+/GM-CSF-receptorbngh' cells had large round to oval nuclei and had small inclusions in the cytoplasm (Fig 6A) . The cells in this subset showed little proliferation during short-term culture (Fig 5) . Instead, proliferation was diminished in the presence of GM-CSF relative to the control. After 3 days of stimulation with GM-CSF, most adhered to the bottom of the culture vessel, which indicated maturation into macrophages and thus showed that this fraction contained the immediate precursors of the CD34-/GM-CSF-receptorhngh' monocytes ( Fig 6B) .
The second subset of CD34' cells expressed GM-CSF receptors at lower levels and displayed intermediate-to-high forward-angle light scatter and heterogeneous right-angle light scatter (Fig 3G) . The light-scatter properties of these cells were distinct from those of the third subset of CD34' cells, which had undetectable GM-CSF-receptor expression and displayed intermediate forward-angle light scatter and very low right-angle light scatter (Fig 3H) . After cell sorting, CD34' cells with intermediate and undetectable GM-CSF receptor expression were morphologically indistinguishable and appeared less mature than the CD34+/GM-CSF-receptorbright cells (Fig 6, C and E) . Both populations consisted of blast-like cells with large nuclei and scanty cytoplasm without granules. After 3 days of stimulation with GM-CSF, CD34+/GM-CSF-receptor intermediate cells showed a strong proliferative response to GM-CSF (Fig 5) . The cells that were produced during this period resembled differentiating monocyte and granulocyte precursors, which indicated that both lineages were represented in this subset (Fig 6D) . The CD34' cells with undetectable GM-CSF-receptor expression also responded to GM-CSF in short-term cultures, but tritiated thymidine incorporation was much less than for the CD34'/GM-CSF-receptor intermediate cells (Fig 5) . During this culture period, most CD34+/GM-CSF-receptornegative cells stayed relatively small and retained a blastlike phenotype (Fig 6F) .
Clonogenic abilities of GM-CSF-receptor-expressing BM cells. Virtually none of the sorted CD34' cells with high GM-CSF-receptor expression and less than 5% of sorted CD34'/GM-CSF-receptor intermediate cells could form torbright colonies in culture, in agreement with the finding that most of the cells in both subsets are relatively mature ( Table 1) . Erythroid and myeloid progenitors were detected in majority in the CD34+ subset with undetectable GM-CSF-receptor expression ( Table 1) . These cells formed colonies in the presence of IL-3, SCF, and GM-CSF, but also in the presence of GM-CSF alone, be it with a lower frequency. The high cloning efficiency of these cells indicated that the relatively weak proliferative response of these cells during shorter culture periods (Fig 5) was not caused by loss of viability as a result of the staining and sorting procedure and that these cells represented an earlier stage of differentiation than the CD34+/GM-CSF-receptor intermediate cells.
Comparison of GM-CSF-receptor expression with R h U -DR expression on CD34' cells. To further characterize the GM-CSF-receptor-positive cells within the CD34' population, three-color FACScan experiments were performed in which GM-CSF-receptor expression was compared with expression of RhLA-DR on CD34' cells, purified by immunomagnetic beads separation. CD34' human BM cells with low HLA-DR expression have been shown to be enriched for immature, multipotent hematopoietic cells whereas high HLA-DR expression is characteristic for activated lineagecommitted progenitors representing later stages of differentia t i~n . '~.~' By analogy, we assumed a similar relation between CD34 and RhLA-DR expression for rhesus monkey BM. As shown in Fig 7, all purified CD34' cells with intermediateto-high GM-CSF-receptor expression coexpressed RhLA-DR at high levels (Fig 7, C and D) . These GM-CSF-receptor expressing cells were found in the CD34b"gh' subset (region 1 in Fig 7A) as well as the subset with lower CD34 expression (region 3). The majority of the cells in the latter population had low forward light scatter (Fig 7B) and undetectable GM-CSF-receptor expression (Fig 7C) . The light-scatter properties of these cells were similar to those of lymphocytes and human pre-B cell^,^^^"^^^' which suggested that these GM-CSF-receptor-negative cells represented B-lymphocyte precursors. High-level GM-CSF-receptor expression could not be detected on the small subset of CD34h"gh' cells with low RhLA-DR expression (region 2 in Fig 7A) . However, the fluorescence histogram of CD34h"gh'/"LA-DRd"'' cells stained with biotin-GM-CSF showed a small shift as compared with control-stained cells in this subset (Fig 7E) . Similar low-level specific binding of biotinylated GM-CSF to CD34h"gh'/RhLA-DRd"'' cells was observed in two additional experiments, which indicated that at least a fraction of the most immature hematopoietic cells identified in normal BM expressed the GM-CSF receptor at low, but detectable levels.
DISCUSSION
In this study, the cellular distribution of GM-CSF receptors in PB and BM has been visualized by means of flow cytometry after staining with biologically active biotin-labeled GM-CSF and fluorescently tagged streptavidin. As based on the ability to detect receptor expression on human hematopoietic cell lines expressing low levels of the high-affinity GM-CSF receptor, the method could detect receptor levels as low as =50 molecules per cell, very similar to that estimated previously for the detection of Epo and IL-6 receptors using fractions was calculated relative to the sort control, which was set at 100%.
biotin-labeled Consistent with the biologic activities of GM-CSF,"6 GM-CSF receptors were detected on mature monocytes and granulocytes, on the immediate BM precursors of these cells and on subsets of immature cells expressing the CD34 antigen. CD34+ cells which expressed the GM-CSF receptor at intermediate-to-high levels coexpressed high levels of the class I1 major histocompatability complex antigen RhLA-DR, whereas GM-CSF receptors on CD34+ cells with low RhLA-DR expression were either absent or expressed at very low levels.
Using a similar approach as described here for GM-CSF, receptors for IL-6, G-CSF, L-3, and SCF have also been detected on CD34-expressing BM Th e receptor for SCF, ie, c-kit, has been shown on the most immature, C ie, CD34+MLA-DRLow cells from human BM3* as well as on long-term repopulating cells in mice?' We have recently found that the IL-3 receptor is also expressed on CD34~@"/ RhLA-DRdU" rhesus monkey BM cells and that these cells are functionally similar to CD34+/HLA-DRd"" human BM cells with respect to high-proliferative and multilineage hematopoietic capacities in vitro."' For this reason, the detection of very low GM-CSF-receptor expression on at least a fraction of the CD34*/RhLA-DRd"L1cells (Fig 7) showed that GM-CSF receptors start to become expressed on the earliest stages of hematopoiesis that can be identified in vitro.
GM-CSF receptors are not expressed on small CD34d""/ RhLA-DRbnght cells (Fig 7) . Although analysis of CD19 expression was not possible because of lack of a suitable anti-
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anti-CD34-FITC biotin-GM-CSF/streptavidin-RPE For personal use only. on October 26, 2017 . by guest www.bloodjournal.org From CD19 antibody that reacts with rhesus monkey cells, these GM-CSF-receptor-negati~e/CD34~""lRhLA-DR~'~g~~ cells (Fig 7C) most likely represented B-lymphocyte precursor cells because of their small size (low forward light scatter) and similarity to the small CD34dU"/CD19f B-lymphocyte progenitor cells that have previously been identified in huThe inability to detect high levels of GM-CSF receptors on the majority of the clonogenic progenitor cells indicated that GM-CSF receptors are either absent on lineage-committed progenitors or are expressed at levels that are below the detection limit of the flow-cytometric method. The ability of sorted CD34' cells with undetectable GM-CSF-receptor expression to form colonies in response to GM-CSF in the absence of added other growth factors would favor the latter possibility and may indicate that very low receptor levels are sufficient for cells to respond to the high GM-CSF concentrations used in culture.
Most of the CD34'/GM-CSF-receptor intermediate cells appeared to have differentiated beyond the clonogenic cells stage, but could still respond to proliferative signals supplied by GM-CSF. The CD34'IGM-CSF-receptor intermediate cell fraction appeared to contain precursors for granulocytes and monocytes because cells of these lineages were produced during short-term liquid culture of sorted cells in the presence of GM-CSF. The inability of CD34' cells with high GM-CSF-receptor expression to proliferate in short-term cultures and in colony assays indicated that these cells represented even later stages of differentiation than the CD34' cells with low-level expression of the GM-CSF receptor. The phenotypic similarity of the CD34'/GM-CSF-receptorbrigh' cells and the CD34-/GM-CSF-receptorhnghh' monocytes, together with the ability of the CD34+/GM-CSF-receptorbrLght cells to adhere to plastic in response to GM-CSF, showed that this subset represented relatively differentiated monocyte precursors. The absence of granulocytic cells in the CD34-/GM-CSF-receptorhnght fraction indicated that there is a more limited increase in GM-CSF receptor levels when granulocyte precursors lose CD34 and mature via RhLA-DR'/CD 1 1 b""" myeloblasts to RhLA-DRd""/CDI 1 b' mature neutrophils. Thus, our findings show that GM-CSF receptors are absent or expressed at very low levels on the earliest stages of hematopoiesis, but are expressed at progressively higher levels during neutrophil and, particularly, monocyte differentiation.
The cellular distribution of GM-CSF receptors thus appears to be different from the expression of the receptor for IL-3, which has been shown to be undetectable on neutrophils and only weakly expressed on (human) monocyte^.^' IL-3 receptors are abundantly expressed on human eosinophils (which also express GM-CSF receptors) and on human and rhesus monkey basophils, which express low levels of the GM-CSF re~eptor.',~'.~' These differences probably reflect independent expression patterns of the LY chains of the GM-CSF receptor and the IL-3 receptor, in particular at the developmentally late stages of hematopoietic cell differentiation, which results in differential distribution on mature cells. This is in agreement with the responses observed following administration of IL-3 and GM-CSF to monkeys: GM-CSF man ~~.34,42.43 predominantly stimulates neutrophil, monocyte, and eosinophil production and IL-3 induces a vigorous basophil re~ponse.~-"
Negative selection of CD34' cells that express high levels of the GM-CSF receptor by using biotin-labeled GM-CSF provides a novel method to deplete developmentally early hematopoietic cells of differentiating monocyte and granulocyte precursors. Biotin-labeled preparations of other HGFs. used separately or in combination, may be similarly used. Such an approach complements conventional cell-separation methods based on depletion of CD34' cells that coexpress differentiation-specific and/or lineage-associated cell surface antigens, such as HLA-DR, CD7 l , and CD19, and identifies immature multilineage hematopoietic cells on the basis of their HGF-receptor phenotype.
